Moxifloxacin Aurobindo (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Aurobindo, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It is employed to treat a range of serious bacterial infections in adult patients, including respiratory, sinus, and intra‑abdominal infections, by inhibiting bacterial DNA replication and transcription. The drug offers a broad‑spectrum option for clinicians managing community‑acquired infections and other qualified indications.

GNH USA supplies Moxifloxacin Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a fluoroquinolone antibiotic indicated for several bacterial infections affecting the respiratory and other systems. - Community‑acquired pneumonia: improves clinical cure rates and reduces bacterial load in adult patients. - Acute bacterial sinusitis: alleviates sinus inflammation and eradicates causative pathogens. - Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents further lung damage. - Skin and skin‑structure infections: resolves cellulitis and related soft‑tissue infections. - Complicated intra‑abdominal infections: provides broad coverage against mixed aerobic and anaerobic organisms.

Moxifloxacin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertiginous sensation. - Abdominal pain: cramping or discomfort. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema. - Clostridioides difficile infection: colitis due to gut flora disruption. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Photosensitivity: heightened skin reaction to sunlight.

When prescribing Moxifloxacin, clinicians should consider several safety precautions to minimise risk. - Assess renal and hepatic function: adjust monitoring in patients with impairment. - Avoid in patients with known hypersensitivity to fluoroquinolones. - Use caution in individuals with a history of tendon disorders. - Monitor cardiac rhythm in patients taking other QT‑prolonging agents. - Avoid concomitant use with antacids containing aluminum or magnesium: may reduce absorption. - Store at room temperature (below 25 °C): keep in original packaging, protect from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other fluoroquinolones: increased risk of tendon toxicity. - Co‑administration with systemic corticosteroids: heightened tendon rupture risk. - Combination with drugs that prolong QT interval (e.g., quinidine, macrolides): risk of cardiac arrhythmia. - Use with antacids containing aluminum or magnesium: markedly reduces absorption. - Interaction with warfarin: may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase CNS stimulation. - Theophylline: potential for elevated plasma levels. - Cyclosporine: possible increased concentrations. - Oral contraceptives: reduced effectiveness reported. - Diabetes medications: monitor blood glucose as fluoroquinolones can affect glycemic control.